-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Apellis Pharmaceuticals, Raises Price Target to $52

Benzinga·08/01/2025 19:54:12
Listen to the news
Citigroup analyst Yigal Nochomovitz maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and raises the price target from $46 to $52.